.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The phase 3 YOSEMITE and RHINE trials compared faricimab with aflibercept in adults with center-involving diabetic macular edema. Faricimab was studied using fixed eight-week dosing and a personalised treat-and-extend regimen, while aflibercept was given every eight weeks. Across the trials, faricimab produced vision gains that were comparable with the active comparator while enabling longer treatment intervals for many patients under the personalised regimen. The results are important because treatment burden remains one of the largest practical challenges in chronic DME care. The personalised approach aims to maintain anatomical and functional control while reducing visit and injection frequency when the eye remains stable. For HCPs, however, treat-and-extend should not be interpreted as automatic interval extension. Decisions remain driven by OCT findings, visual response and disease recurrence. The evidence supports a more individualised approach to anti-VEGF care and is directly relevant to AIOC's retina sessions on DME treatment regimens and imaging-guided management.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The phase 3 YOSEMITE and RHINE trials compared faricimab with aflibercept in adults with center-involving diabetic macular edema. Faricimab was studied using fixed eight-week dosing and a personalised treat-and-extend regimen, while aflibercept was given every eight weeks. Across the trials, faricimab produced vision gains that were comparable with the active comparator while enabling longer treatment intervals for many patients under the personalised regimen. The results are important because treatment burden remains one of the largest practical challenges in chronic DME care. The personalised approach aims to maintain anatomical and functional control while reducing visit and injection frequency when the eye remains stable. For HCPs, however, treat-and-extend should not be interpreted as automatic interval extension. Decisions remain driven by OCT findings, visual response and disease recurrence. The evidence supports a more individualised approach to anti-VEGF care and is directly relevant to AIOC's retina sessions on DME treatment regimens and imaging-guided management.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
